Cuscal Limited has successfully completed a A$30 million institutional placement, raising capital to fund its acquisition of Paymark Limited. The company issued approximately 7.5 million new fully paid ordinary shares at A$4.00 per share, representing a 5.0% discount to the company’s last closing price of A$4.21 on 13 April 2026. The placement was strongly supported by both existing shareholders and new institutional investors, demonstrating market confidence in the strategic direction of the business.
The pricing of the institutional placement sits at a modest discount to recent trading levels. The A$4.00 placement price represents a 3.9% discount to the five-day volume-weighted average price of A$4.16, suggesting the discount was sufficient to attract institutional participation without materially diluting existing shareholder value. This pricing approach is typical for capital raises of this nature, balancing the need to ensure placement success with minimising dilution to the shareholder base.
Beyond the institutional placement, Cuscal is offering eligible Australian and New Zealand shareholders the opportunity to participate in a non-underwritten share purchase plan targeting up to A$3 million in additional capital. Eligible shareholders can subscribe for up to A$30,000 worth of shares at no brokerage or transaction costs. The SPP shares will be priced at the lower of the A$4.00 placement price and a 1.5% discount to the five-day VWAP calculated up to the SPP closing date, providing existing shareholders with potential upside compared to the institutional placement price.
The Paymark acquisition represents a strategically aligned opportunity for Cuscal, according to managing director Craig Kennedy. The company characterises the acquisition as offering value creation through strong standalone economics, limited integration complexity, and the potential to deliver sustainable long-term returns. This positioning suggests Cuscal views Paymark as a complementary business rather than requiring extensive operational restructuring post-acquisition.
From a procedural standpoint, the placement was undertaken within Cuscal’s existing placement capacity under ASX Listing Rule 7.1, meaning shareholder approval was not required. Settlement of the new shares is expected on 17 April 2026, with allotment and normal trading commencing on 20 April 2026. The new shares issued will rank equally with all existing fully paid ordinary shares, ensuring parity for all shareholders.
Investors should monitor the completion of the Paymark acquisition itself, as this will provide insight into the strategic rationale behind this capital raise and the management team’s ability to execute on acquisition integration. Additionally, tracking the take-up rate of the share purchase plan among existing shareholders will provide signals about shareholder sentiment towards the acquisition. The announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About CCL (ASX: CCL)
CCL is listed on the Australian Securities Exchange (ASX: CCL).
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
